NEWS

Our Latest News

ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising.

 

 

ARCHIMED closes MED IV fund at €1.5 billion ($1.75 billion) hard cap, three times oversubscribed, in less than six months of fundraising.

ARCHIMED acquires Jeisys Medical, a leading developer of aesthetic medicine devices

 September

 11, 

2024

ARCHIMED buys Cellese, a pioneering developer of growth factors and exosome-based skincare products

 September

 4, 

2024

ARCHIMED acquires Irrimax, market leader in anti-microbial wound irrigation solutions

 August

 28, 

2024

Majority owner ARCHIMED and its partners fund three add-on acquisitions by diversified European health safety testing company, CARSO

 May

 6, 

2024

ARCHIMED concludes successfully its £203 million take-private bid for drug development software leader Instem

 November

 27, 

2023

ARCHIMED creates a leading specialized dermatological-focused CRO via the simultaneous purchase & merger of Symbio and Proinnovera

 November

 17, 

2023

1 … 3 4 5 6 7 … 18
368